Albemarle (ALB) Sees a More Significant Dip Than Broader Market: Some Facts to Know

11.06.26 00:00 Uhr

Werte in diesem Artikel
Aktien

118,50 EUR 0,75 EUR 0,64%

Indizes

1.854,4 PKT -8,4 PKT -0,45%

7.483,2 PKT 0,0 PKT 0,00%

Albemarle (ALB) closed the most recent trading day at $147.22, moving -3.65% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow lost 1.87%, and the Nasdaq, a tech-heavy index, lost 1.98%. Prior to today's trading, shares of the specialty chemicals company had lost 25.66% lagged the Basic Materials sector's loss of 5.57% and the S&P 500's loss of 0.03%.Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. In that report, analysts expect Albemarle to post earnings of $3.08 per share. This would mark year-over-year growth of 2700%. Meanwhile, the latest consensus estimate predicts the revenue to be $1.48 billion, indicating a 11.36% increase compared to the same quarter of the previous year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $12.39 per share and a revenue of $5.99 billion, signifying shifts of +1668.35% and +16.45%, respectively, from the last year. Any recent changes to analyst estimates for Albemarle should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 38.76% higher within the past month. As of now, Albemarle holds a Zacks Rank of #1 (Strong Buy). From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 12.34. This valuation marks a discount compared to its industry average Forward P/E of 16.29. Also, we should mention that ALB has a PEG ratio of 0.77. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Chemical - Diversified industry currently had an average PEG ratio of 1.23 as of yesterday's close. The Chemical - Diversified industry is part of the Basic Materials sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 36% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow ALB in the coming trading sessions, be sure to utilize Zacks.com. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Albemarle und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Albemarle Corp.

Analysen zu Albemarle Corp.

DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
10.11.2017Albemarle OutperformRBC Capital Markets
09.11.2017Albemarle NeutralUBS AG
27.10.2017Albemarle OutperformBMO Capital Markets
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
10.11.2017Albemarle OutperformRBC Capital Markets
27.10.2017Albemarle OutperformBMO Capital Markets
08.05.2017Albemarle OutperformRBC Capital Markets
17.03.2017Albemarle OutperformRBC Capital Markets
01.03.2017Albemarle OutperformRBC Capital Markets
DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
09.11.2017Albemarle NeutralUBS AG
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
10.03.2016Albemarle NeutralSeaport Global Securities
03.02.2015Albemarle Market PerformCowen and Company, LLC
DatumRatingAnalyst
16.08.2011Albemarle underperformOppenheimer & Co. Inc.
04.01.2006Update Albemarle Corp.: UnderweightJP Morgan

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Albemarle Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen